abstract/full text: Gene silencing of glypican-3 in clear cell carcinoma of the ovary renders it more sensitive to the apoptotic agent paclitaxel

"Clear cell carcinoma has been classified as a subgroup of EOC and reported to be an interesting histologic type with unique clinical features. CCC showed a poorer prognosis compared to serous adenocarcinoma because it tended to be resistant to antineoplastic agents, including paclitaxel.

CCC comprises more than 15% of EOC cases in Japan, although it represents 8–10% of all EOC cases in the USA. Therefore, it is important to establish new treatment strategies to improve the prognosis of CCC patients.

GPC3 regulates cell growth either positively or negatively depending on the cell type. Genetic and functional studies showed that glypicans regulate the signaling activity of various morphogens, including Wnts, Hedgehogs, bone morphogenic proteins, and fibroblast growth factors. Previous studies showed that GPC3 was overexpressed in Wilms' tumor, hepatocellular carcinoma, and hepatoblastoma. In ovarian carcinoma, GPC3 was overexpressed in yolk sac tumor and CCC.(15–17) However, GPC3 function in CCC was unclear. Furthermore, we investigated the role of this molecule in the sensitivity of CCC to paclitaxel, which is a key drug for ovarian cancer, using shRNA targeting GPC3.

Taken together, our data could support the use of GPC3-targeted therapies for CCC patients. We suggest that therapy targeting to GPC3 may be a novel treatment strategy that could potentially help to prevent the appearance, progression, and/or recurrence of CCC."

full free access:
http://www3.interscience.wiley.com/cgi-bin/fulltext/122614981/HTMLSTART

free full access: Cardiotoxicity of Anticancer Drugs: The Need for Cardio-Oncology and Cardio-Oncological Prevention -- JNCI

Longwoods Publishing - TOP TEN BEST READ DOCUMENTS/ARTICLES FOR DECEMBER 2009

TOP TEN BEST READ DOCUMENTS/ARTICLES FOR DECEMBER 2009

(as measured by actual access from the longwood.com web site)

Saskatchewan Patient First Review - Patient Experience Final Report (PDF) The Day We Stop Caring | Caregiving for the Future. (PDF) Adalsteinn Brown, Breakfast With The Chiefs, May 13, 2009 Lifting The Burden Of Chronic Disease | What's Worked | What Hasn't | What Next (PDF) - Directional Document. Sara Kreindler, D.Phil., Winnipeg Regional Health Authority, Research & Evaluation Unit. May, 2008 A Return to Diploma-Prepared Registered Nurses. June F. Kikuchi Research Distilled: Enabling Intelligent Decisions; Focus: Healthcare Information Systems. KLAS Where There's Smoke, There's Pfizer: Sparks Fly Over Recent CIHR Appointment. Steven Lewis Effects of Leadership and Span of Control on Nurses' Job Satisfaction and Patient Satisfaction. Amy Sanchez McCutcheon, Diane Doran, Martin Evans, Linda McGillis Hall and Dorothy Pringle The Conference Board: Rank Amateurs with an Agenda? Steven Lewis Ten Key Principles for Successful Health Systems Integration. Esther Suter, Nelly D. Oelke, Carol E. Adair and Gail D. Armitag Bottom-Up vs. Top-Down Innovation - and Hot Air. Neil Seeman

Overview/Basics: Epithelial Ovarian Cancer (The Doctor Will See You Now)

Bevacizumab (Avastin) Safety in Patients with Central Nervous System Metastases — Clinical Cancer Research

Analysis of Contemporary Trends in Access to High-Volume Ovarian Cancer Surgical Care

Breast-Conserving Surgery in BRCA1/2 Mutation Carriers: Are We Approaching an Answer?

How strong is the evidence that solar ultraviolet B and vitamin D reduce the risk of cancer?: An examination using Hill's criteria for causality.

full free access: Conditional Inactivation of Brca1, p53 and Rb in Mouse Ovaries Results in the Development of Leiomyosarcomas

2nd article

full free access: Induction of Ovarian Leiomyosarcomas in Mice by Conditional Inactivation of Brca1 and p53